This "new" drug is a COMT inhibitor intended for use with CARBI/LEVO in PD. It was compared to entacapone in clinical trials to extend ON time in patients where Ongentys was found to be "at least as effective" as entacapone. It is a "me too" drug produced by a Portugese company in 25 and 50 mg capsules to be added to basic carb/levo or benzseride/levo just like entatapone, aka Comtan, which has been around many years. Stalevo combines all three; carbidopa, levodopa and entacapone.